---
title: "Inhibrx Biosciences Secures $150M Loan for Growth"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/224810530.md"
description: "Inhibrx Biosciences, Inc. has secured a $150 million loan from Oxford Finance LLC, with an initial funding of $100 million. This loan agreement, which includes warrants for lenders, aims to provide financial flexibility for advancing clinical programs INBRX-109 and INBRX-106, expected to yield key data in 2025. The funding is set to enhance Inhibrx's position in the biopharmaceutical sector and support the development of its innovative therapeutic pipeline. The company's current market cap stands at $205.7 million, with a year-to-date price performance of -6.82%."
datetime: "2025-01-13T21:50:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/224810530.md)
  - [en](https://longbridge.com/en/news/224810530.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/224810530.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/224810530.md) | [English](https://longbridge.com/en/news/224810530.md)


# Inhibrx Biosciences Secures $150M Loan for Growth

### Stay Ahead of the Market:

-   Discover outperforming stocks and invest smarter with Top Smart Score Stocks
-   Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener

An update from Inhibrx Biosciences Inc ( (INBX) ) is now available.

Inhibrx Biosciences, Inc. announced a loan and security agreement with Oxford Finance LLC, securing a term loan facility of up to $150 million, with an initial funding of $100 million. The agreement, which includes issuing warrants to the lenders, provides Inhibrx with strategic financial flexibility to advance its clinical programs, INBRX-109 and INBRX-106, both expected to have key data readouts in 2025. This financial support is anticipated to bolster Inhibrx’s position in the biopharmaceutical industry, aiding in the further development of its innovative therapeutic pipeline.

**More about Inhibrx Biosciences Inc**

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focusing on developing a broad pipeline of novel biologic therapeutic candidates. The company utilizes diverse protein engineering methods to address complex target and disease biology, leveraging proprietary protein engineering platforms. With ongoing programs such as INBRX-109 and INBRX-106, Inhibrx aims to optimize therapeutic candidates for specific biological targets.

**YTD Price Performance:** -6.82%

**Average Trading Volume:** 69,185

**Technical Sentiment Consensus Rating:** Strong Buy

**Current Market Cap:** $205.7M

For detailed information about INBX stock, go to TipRanks’ Stock Analysis page.

## Trending Articles:

-   Disney (NYSE:DIS) Slapped With $10 Billion Lawsuit Over “Moana 2”
-   Ford (NYSE:F) Makes the Most of Quiet Detroit Auto Show
-   Can Intel (NASDAQ:INTC) Spark an AI-Fueled Comeback in 2025?

### 相關股票

- [Inhibrx Biosciences (INBX.US)](https://longbridge.com/zh-HK/quote/INBX.US.md)
- [Manhattan Bridge Capital (LOAN.US)](https://longbridge.com/zh-HK/quote/LOAN.US.md)

## 相關資訊與研究

- [Inhibrx Advances INBRX-106, Ozekibart Programs, Key Milestones Expected Next Year](https://longbridge.com/zh-HK/news/269975336.md)
- [Inhibrx Biosciences Reports Promising Q3 2025 Results](https://longbridge.com/zh-HK/news/267278377.md)
- [12:36 ETEmergetic Sports Announces Gabe Feldman as Senior Education Advisor](https://longbridge.com/zh-HK/news/281402214.md)
- [Northstar Raises US$9 Million in Convertible Debenture Financing to Support Growth](https://longbridge.com/zh-HK/news/281256488.md)
- [Inhibrx Biosciences Highlights 2026 Pipeline and Strategy](https://longbridge.com/zh-HK/news/276615408.md)